Wolfgang Wick
Computer Vision and Pattern Recognition · 2002–2021
A researcher in the Science corpus: 36 papers; trusts 41 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Computer Vision and Pattern Recognition — 53 citations into it
- Artificial Intelligence — 38 citations into it
- Biomedical Engineering — 16 citations into it
- Model Architectures — 16 citations into it
- Biophysics — 7 citations into it
- Optimization & Training — 7 citations into it
- Management Science and Operations Research — 6 citations into it
- Media Technology — 5 citations into it
Whom Wolfgang Wick trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Kaiming He
- Olaf Ronneberger
- Diederik P. Kingma
- Konstantinos Kamnitsas
- Fausto Milletarì
- Geoffrey E. Hinton
- Evan Shelhamer
- Alex Krizhevsky
- X. Zhang
- Jimmy Ba
Who trusts Wolfgang Wick overall
Papers from Wolfgang Wick's perspective
Ordered by how strongly the researchers Wolfgang Wick trusts endorse each paper. Same corpus, a different order for every researcher.
- Adam: A Method for Stochastic Optimization (International Conference on Learning Representations)
- ImageNet classification with deep convolutional neural networks
- Deep Residual Learning for Image Recognition (Computer Vision and Pattern Recognition)
- Batch Normalization: Accelerating Deep Network Training by Reducing Internal Covariate Shift (International Conference on Machine Learning)
- Gradient-based learning applied to document recognition
- Very Deep Convolutional Networks for Large-Scale Image Recognition (International Conference on Learning Representations)
- ImageNet: A large-scale hierarchical image database
- Fully convolutional networks for semantic segmentation
- Going deeper with convolutions
- Attention is All you Need (Neural Information Processing Systems)
Their papers
- Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. (2008) — 727 citations
- Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. (2008) — 818 citations
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010) — 766 citations
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor (2011) — 1,776 citations
- Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. (2014) — 2,250 citations
- Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo (2002) — 751 citations
- DNA methylation-based classification of central nervous system tumours (2018) — 2,473 citations
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. (2014) — 903 citations
- Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. (2012) — 643 citations
- Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas (2021) — 196 citations
- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) — 972 citations
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020) — 1,588 citations
- How to use and assess qualitative research methods (2020) — 1,254 citations
- Glutamatergic synaptic input to glioma cells drives brain tumour progression (2019) — 990 citations
- Automated brain extraction of multisequence MRI using artificial neural networks (2019) — 710 citations
- Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. (2019) — 375 citations
- Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) — 806 citations
- No New-Net (2018) — 444 citations
- Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma (2017) — 956 citations
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. (2017) — 913 citations